Precision pharmacotherapy: psychiatry’s future direction in preventing, diagnosing, and treating mental disorders
Open accessThe DOI matches its Crossref record; 181 of the 184 references it cites were found in a registry or an index.
Abstract
Mental disorders account for around one-third of disability worldwide and cause enormous personal and societal burden. Current pharmacotherapies and nonpharmacotherapies do help many patients, but there are still high rates of partial or no response, delayed effect, and unfavorable adverse effects. The current diagnostic taxonomy of mental disorders by the Diagnostic and Statistical Manual of Mental Disorders and the International Classification of Diseases relies on presenting signs and symptoms, but does not reflect evidence from neurobiological and behavioral systems. However, in the last decades, the understanding of biological mechanisms underlying mental disorders has grown and can be used for the development of precision medicine, that is, to deliver a patient-tailored individual treatment. Precision medicine may incorporate genetic variants contributing to the mental disorder and the response to pharmacotherapies, but also consider gene ¥ environment interactions, blood-based markers, neuropsychological tests, data from electronic health records, early life adversity, stressful life events, and very proximal factors such as lifestyle, nutrition, and sport. Methods such as artificial intelligence and the underlying machine learning and deep learning approaches provide the framework to stratify patients, initiate specific tailored treatments and thus increase response rates, reduce adverse effects and medical errors. In conclusion, precision medicine uses measurable health parameters to identify individuals at risk of a mental disorder, to improve the diagnostic process and to deliver a patient-tailored treatment. Keywords: precision medicine, personalized medicine, biomarker, mental health, depression, childhood trauma, FKBP5, machine learning
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings again support the notion that drugs with very narrow specific mechanisms are only effective in patients with corresponding pathophysiology and that a matching of patients with treatment options using biomarkers or genetic markers is necessary [14].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To match the patient with the right treatment approach in terms of an individualized treatment, it is necessary to apply tests that assess the function of the HPA axis, such as the dex-CRH test or the molecular DST [14, 47].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatologist-level classification of skin cancer with deep neural networks
Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017) · Nature · doi:10.1038/nature21056 · Cited by 14,362
Biological insights from 108 schizophrenia-associated genetic loci
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) · Nature · doi:10.1038/nature13595 · Cited by 7,577
Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K., Sanislow, C., & Wang, P. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09091379 · Cited by 7,067 · cited 3×
“In addition, the current diagnostic frameworks with Diagnostic and Statistical Manual of Mental Disorders (DSM) published by the American Psychiatric Association and the International Classification of Diseases (ICD) developed by the World Health Organization rely on presenting signs and symptoms but fail to align wit…”
MethodKirschbaum, C., Pirke, K.-M., & Hellhammer, D. H. (2008) · Neuropsychobiology · doi:10.1159/000119004 · Cited by 6,093
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Stress and the brain: from adaptation to disease
de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754
Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800389 · Cited by 3,616
Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases
Pedersen, B. K., & Saltin, B. (2015) · Scandinavian Journal of Medicine & Science in Sports · doi:10.1111/sms.12581 · Cited by 3,514
The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses
Hofmann, S. G., Asnaani, A., Vonk, I. J. J., Sawyer, A. T., & Fang, A. (2012) · Cognitive Therapy and Research · doi:10.1007/s10608-012-9476-1 · Cited by 3,445 · cited 1×
“Moreover, current drug treatment options are successful only in about half of the patients,(149) and similar considerations apply to nonpharmacologic treatment options such as psychotherapy.(150) There are many reasons for this unfavorable condition; the brain is the most complex organ in the body, and mental disorder…”
Background
Research works printed but not linked: 3
- [15]15. Wium-Andersen IK, Vinberg M, Kessing LV, McIntyre RS. Personal- ized medicine in psychiatry. Nord J Psychiatry. 2017;71(1):12-19.
- [113]113. Brandl EJ, Kennedy JL, Müller DJ. Pharmacogenetics of antipsychot- ics. Can J Psychiatry. 2014;59(2):76-88.
- [128]128. Yu S-H, Liu S-K, Lin K-M. Psychopharmacology across cultures. In: Bhugra D, Bhui K, editors. Textbook of Cultural Psychiatry. 1st ed. Cambridge, UK: Cambridge University Press; 2007:402-413.
Cited by
Lee, E. E., Torous, J., De Choudhury, M., Depp, C. A., Graham, S. A., Kim, H.-C., Paulus, M. P., Krystal, J. H., & Jeste, D. V. (2021) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2021.02.001 · Cited by 429
Jacobs, M., Pradier, M. F., McCoy, T. H., Perlis, R. H., Doshi-Velez, F., & Gajos, K. Z. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01224-x · Cited by 247
Is the HPA Axis as Target for Depression Outdated, or Is There a New Hope?
Menke, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00101 · Cited by 240
“Various factors may explain the current situation: MDD is a heterogeneous condition with poorly defined endophenotypes or subgroups, the currently available drugs have very similar treatment mechanisms and target almost only components of the serotonin, norepinephrine, or dopamine signaling, and there are no biomarker…”
BackgroundSelf-citationJacobs, M., He, J., F. Pradier, M., Lam, B., Ahn, A. C., McCoy, T. H., Perlis, R. H., Doshi-Velez, F., & Gajos, K. Z. (2021) · Proceedings of the 2021 CHI Conference on Human Factors in Computing Systems · doi:10.1145/3411764.3445385 · Cited by 177
“The trial and error involved in identifying effective treatment for a given individual has prompted calls for more integration of evidence-based medicine in the treatment of mental health disorders [40, 48, 58].”
BackgroundThe HPA Axis as Target for Depression
Menke, A. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230811141557 · Cited by 131
“To match the patient with the right treatment approach in terms of an individualized treatment, it is necessary to apply tests that assess the function of the HPA axis, such as the dex-CRH test or the molecular DST [14, 47].”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Menke, A.
- Affiliations
- University of Würzburg (DE)
- Corresponding author
- Menke, Andreas
- ORCID
- Menke, Andreas
- Venue
- Pharmacogenomics and Personalized Medicine
- Publisher
- Informa UK Limited
- Published
- 2018-11
- Volume
- Volume 11
- Pages
- 211-222
- ISSN
- 1178-7066 (ISSN-L)
- PMC
- PMC6250105
- OpenAlex
- W2900736680
- Cited by
- 41
- References
- 184
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 1 · 2023: 5 · 2022: 3 · 2021: 11 · 2020: 11 · 2019: 5
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmacogenomics and Personalized Medicine (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- precision medicine, precision psychiatry, mental illness, pharmacotherapy response, biomarkers, genetic variants, gene-environment interaction, machine learning, artificial intelligence, depression, childhood trauma, FKBP5, electronic health records, neuropsychological assessment, childhood adversity, adverse drug reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.